In the murine model of Stiff et al., treatment with ibrutinib resulted in a reduced frequency of MDSCs in mammary tumors and significantly improved the efficacy of anti-PD-L1 therapy in breast cancer, possibly providing a novel strategy for enhancing immune therapies in solid malignancies [35]. This evidence concerns the gene CD274 and breast carcinoma.